Document Detail


Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis.
MedLine Citation:
PMID:  11431016     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IL-12 is a key cytokine for Th1 cell development and may be important in the pathogenesis of multiple sclerosis (MS). The beta2-agonist salbutamol is known to decrease IL-12 production in monocytes of normal individuals through increased intracellular cAMP. In a prospective open-label study, we investigated by flow cytometry the effect of a 2-week long oral salbutamol treatment on monocyte IL-12 production in 21 secondary progressive MS patients. Baseline IL-12 production was higher in patients than in healthy controls. The treatment induced a significant decrease in the percentage of IL-12-producing monocytes and dendritic cells that lasted up to 1 week after treatment interruption. This first report on the use of salbutamol in MS shows that this drug has immunomodulatory properties both in vivo and in vitro, and may be beneficial in the treatment of MS.
Authors:
K Makhlouf; M Comabella; J Imitola; H L Weiner; S J Khoury
Related Documents :
22562066 - Delivery of p-glycoprotein substrates using chemosensitizers and nanotechnology for sel...
22906146 - Molecular cloning and functional characterization of an atp-binding cassette transporte...
15082336 - Principles of transmucosal delivery of therapeutic agents.
21833176 - Stereoselective inhibition of the herg1 potassium channel.
20123556 - Neuroprotection in parkinson's disease.
23437766 - Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resista...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of neuroimmunology     Volume:  117     ISSN:  0165-5728     ISO Abbreviation:  J. Neuroimmunol.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-06-29     Completed Date:  2001-08-23     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8109498     Medline TA:  J Neuroimmunol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  156-65     Citation Subset:  IM    
Affiliation:
Center for Neurologic Diseases, Brigham and Women's Hospital, and Harvard Medical School, 77 Louis Pasteur Avenue, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adrenergic beta-Agonists / pharmacology*
Adult
Albuterol / administration & dosage,  pharmacology*,  therapeutic use
Antigens, CD40 / biosynthesis
Antigens, CD80 / biosynthesis
Bucladesine / pharmacology
Dendritic Cells / drug effects,  metabolism
Female
Humans
Interleukin-12 / biosynthesis*
Lipopolysaccharides / pharmacology
Male
Middle Aged
Monocytes / drug effects,  metabolism
Multiple Sclerosis / drug therapy*,  immunology
Grant Support
ID/Acronym/Agency:
1P01NS38037/NS/NINDS NIH HHS; N01AI05411/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Antigens, CD40; 0/Antigens, CD80; 0/Lipopolysaccharides; 18559-94-9/Albuterol; 187348-17-0/Interleukin-12; 362-74-3/Bucladesine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  IgG reactivity against citrullinated myelin basic protein in multiple sclerosis.
Next Document:  Induction of selected chemokines in glial cells infected with Theiler's virus.